Laboratory for Thrombosis Research, KU Leuven Kulak, Kortrijk, Belgium.
J Thromb Haemost. 2015 Feb;13(2):283-92. doi: 10.1111/jth.12804. Epub 2015 Jan 17.
Congenital thrombotic thrombocytopenic purpura (TTP) is characterized by mutations in the ADAMTS13 gene, which either impair protein secretion or influence ADAMTS13 (A Disintegrin-like And Metalloprotease domain with ThromboSpondin type-1 motif, member 13) activity. Phenotypic consequences of these mutations have not yet been evaluated in animal models for TTP.
To identify the in vitro effect of a novel ADAMTS13 mutation and to investigate whether this mutation induces TTP in vivo.
All 29 ADAMTS13 exons with exon-intron boundaries of a patient with pregnancy-onset TTP were sequenced. Wild-type and mutant ADAMTS13 proteins were both transiently and stably expressed in human embryonic kidney cells, and their activity was evaluated in vitro using fluorescence resonance energy transfer and flow assays. Molecular dynamics simulations were performed to study Ca(2+) stability. Adamts13(-/-) mice were hydrodynamically injected with wild-type and mutant expression plasmids and triggered with recombinant human von Willebrand factor.
We identified a novel heterozygous c.559G>C mutation in exon 6 of the proposita's ADAMTS13 gene. This mutation resulted in a p.Asp187His substitution (p.D187H), which was located in the high affinity Ca(2+) -binding site in the metalloprotease domain of ADAMTS13. The homozygous p.D187H mutation down-regulated ADAMTS13 activity in vitro. Impaired proteolytic activity was linked to unstable Ca(2+) binding as visualized using a molecular dynamics simulation. In addition, the p.D187H mutation affects protein secretion in vitro. In Adamts13(-/-) mice, the homozygous p.D187H mutation reduced ADAMTS13 secretion and activity and contributed to TTP when these mice were triggered with recombinant human von Willebrand factor.
Our data indicate that the p.D187H mutation impairs ADAMTS13 activity and secretion and is responsible for TTP onset in mice.
先天性血栓性血小板减少性紫癜(TTP)的特征是 ADAMTS13 基因突变,这些突变要么损害蛋白分泌,要么影响 ADAMTS13(一种具有血小板反应蛋白 1 型基序的解整合素和金属蛋白酶域 13)活性。这些突变的表型后果尚未在 TTP 的动物模型中进行评估。
确定一种新型 ADAMTS13 突变的体外效应,并研究该突变是否在体内诱导 TTP。
对一名妊娠相关性 TTP 患者的所有 29 个 ADAMTS13 外显子及其内含子边界进行测序。野生型和突变型 ADAMTS13 蛋白均在人胚肾细胞中瞬时和稳定表达,并通过荧光共振能量转移和流式细胞术评估其体外活性。进行分子动力学模拟以研究 Ca(2+)稳定性。用重组人血管性血友病因子对 Adamts13(-/-) 小鼠进行水力注射野生型和突变型表达质粒,并进行触发。
我们在先证者的 ADAMTS13 基因的第 6 个外显子中发现了一种新的杂合 c.559G>C 突变。该突变导致 p.Asp187His 取代(p.D187H),该取代位于 ADAMTS13 金属蛋白酶域中的高亲和力 Ca(2+)结合位点。该纯合 p.D187H 突变降低了 ADAMTS13 的体外活性。使用分子动力学模拟观察到,不稳定的 Ca(2+)结合与酶切活性降低有关。此外,该 p.D187H 突变影响体外蛋白分泌。在 Adamts13(-/-) 小鼠中,该纯合 p.D187H 突变降低了 ADAMTS13 的分泌和活性,并在这些小鼠用重组人血管性血友病因子触发时导致 TTP。
我们的数据表明,p.D187H 突变损害 ADAMTS13 的活性和分泌,并导致小鼠 TTP 的发生。